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Abstract The sensitive and specific detection of analytes
such as proteins in biological samples is critical for a
variety of applications, for example disease diagnosis. In
immunoassays a signal in response to the concentration of
analyte present is generated by use of antibodies labeled
with radioisotopes, luminophores, or enzymes. All immu-
noassays suffer to some extent from the problem of the
background signal observed in the absence of analyte,
which limits the sensitivity and dynamic range that can be
achieved. This is especially the case for homogeneous
immunoassays and surface measurements on tissue sections
and membranes, which typically have a high background
because of sample autofluorescence. One way of minimiz-
ing background in immunoassays involves the use of
lanthanide chelate labels. Luminescent lanthanide com-
plexes have exceedingly long-lived luminescence in com-
parison with conventional fluorophores, enabling the short-
lived background interferences to be removed via time-
gated acquisition and delivering greater assay sensitivity
and a broader dynamic range. This review highlights the
potential of using lanthanide luminescence to design
sensitive and specific immunoassays. Techniques for
labeling biomolecules with lanthanide chelate tags are
discussed, with aspects of chelate design. Microtitre plate-
based heterogeneous and homogeneous assays are reviewed
and compared in terms of sensitivity, dynamic range, and
convenience. The great potential of surface-based time-
resolved imaging techniques for biomolecules on gels,
membranes, and tissue sections using lanthanide tracers in
proteomics applications is also emphasized.
Keywords Bioassays.Fluorescence/luminescence.Rare
earth elements.Genomics/proteomics.Bioanalytical
methods
Introduction
The detection of particular analytes is the cornerstone of
analytical chemistry and is crucial for a plethora of different
applications, ranging from protein detection to drug
screening and mapping of biochemical pathways. Two vital
features of the ideal assay are specificity and sensitivity—
that is, the analyte of interest should be:
1. unambiguously detected even when potentially inter-
fering substances are present in excess, and
2. detectable at the low concentrations typically required
for most applications.
In protein detection, these problems are especially chal-
lenging to solve. First, biological samples are highly complex
and contain a huge number of different proteins, making the
detection of one specific protein a special challenge. Second,
some proteins are expressed in extremely low copy numbers,
especially in the early stages of disease. Third, biological
samples containing proteins have high background fluores-
cence, making it difficult to obtain good sensitivity using
simple fluorophores. Last, but not least, the difference
between high-abundance and low-abundance proteins in one
biological sample can span an estimated twelve orders of
magnitude [1]. This requires detection methods with broad
linear ranges. In general, time-resolved luminescence is an
ideal tool to meet all of these challenges. As will be
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vides excellent detection limits but also broadens the linear
range of existing protein detection assays, because of the low
background signals associated with this method.
In immunoassays the specificity is provided by antibodies
raised against the analyte of interest, whereas sensitivity relies
on some form of coupling of analyte–antibody binding with a
detectable and quantifiable signal. In the simplest format this
involves direct labeling of the antibody with a small molecule
tag, for example a radioisotope or luminophore, which can
then be detected using appropriate analytical devices. A
variety of assay formats are also possible, including well
plate-based assays in which the antigen of interest is either
immobilized on the well plate surface or present in solution,
membrane-basedassaysinwhichproteinsareseparatedbygel
electrophoresis and subsequently transferred to a membrane
for detection, and direct staining of tissue sections for
examination under a fluorescence microscope.
The objective of this critical review is to highlight the
potential of lanthanide-based time-resolved luminescence for
developing ultrasensitive immunoassays. The basic principles
behind immunoassays (in the section “Immunoassays”)a n d
time-resolved luminescence measurements (in the section
“Lanthanide luminescence”) will be discussed, followed by a
thorough overview of the main techniques for labeling
biomolecules with lanthanides via various chelating groups
(in the section “Chelator design and lanthanide labeling of
biomolecules”). The remainder of the review will focus on
reported immunoassays using lanthanide-based lumines-
cence detection and will be divided into two main sections:
the well-established field of microtitre plate-based assays,
encompassing heterogeneous and homogeneous assays (the
section “Microtitre plate-based assays”), and the nascent but
promising field of imaging-based methods such as mem-
brane imaging and time-resolved luminescence microscopy
(in the section “Surface-based assays”).
Immunoassays
The term “immunoassay” refers to the use of antibodies
raised against an analyte of interest (antigen) as a means of
detecting the presence of that analyte. Because neither
antibodies nor their binding to their antigens have high
intrinsic detectability, the use of antibodies as detection
reagents requires some form of labeling of the antibody
with an easily detectable reporter molecule. The conceptu-
ally simplest reporters consist of antibodies directly labeled
with either an enzyme or small molecule light absorbers,
fluorophores, or radioisotopes, although indirect labeling
via a species-specific secondary antibody or the biotin–
streptavidin interaction results in greater versatility and
some signal amplification.
The first immunoassays used antibodies labeled with
radioisotopes that could subsequently be detected by use of
scintillation counters. Although highly sensitive, the prob-
lems associated with radioisotopes (limited stability, safe
disposal, etc.) have led to the development of alternative
detection strategies, of which the most widespread is
currently the use of antibody–enzyme conjugates, in which
enzymatic turnover converts an uncolored substrate to a
colored product which can be quantified colorimetrically.
These assays have the advantage of amplification—that is,
conversion of a single antibody–enzyme immunocomplex
into multiple detectable molecules. However, the linear
range of colorimetric detection is limited and the color-
development process necessitates additional time, steps,
and reagents. Antibody–fluorophore conjugates have the
potential to eliminate some of these problems, because the
fluorescence of the immunocomplex can be measured
directly on the surface or in solution. However, they suffer
from the disadvantage that no amplification occurs,
requiring very bright luminescence output from each
luminophore or high degrees of labeling. The latter can be
difficult to achieve without compromising antibody activity
or solubility. One way of achieving high sensitivity in
luminescence-based assays entails the use of time-resolved
luminescence measurements to minimize the sample back-
ground. The advantages of using time-resolved lumines-
cence for immunodetection will be the focus of this review.
Four basic assay configurations are possible, depending
on whether the immunoreaction occurs on a solid phase
(heterogeneous) or in solution (homogeneous) and whether
the antibody–analyte binding is monitored directly (non-
competitive) or via displacement of a labeled antigen
(competitive). Typical solid phases for a heterogeneous
immunoassay include microtitre plates, membranes and
tissue slices, to which the antigen is either bound directly or
on which it is captured by use of an appropriate antibody
(Fig. 1). The presence of this antigen can then be
determined after binding an appropriately labeled antibody
(or primary–secondary antibody combination) and measur-
ing, e.g., the luminescence signal. A typical homogeneous
non-competitive assay utilizes two differently labeled anti-
bodies which interact with one another in some way (e.g.
by luminescence resonance energy transfer, LRET) in the
presence of the target antigen (Fig. 1), whereas a homoge-
neous competitive assay could involve a system whereby
the target antigen displaces a labeled antigen analogue from
a labeled antibody and thereby reduces the LRET intensity.
Lanthanide luminescence
Luminescence is the process in which a species absorbs
light at one wavelength and subsequently emits it at a
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tion excites the molecule from its ground state singlet
electronic level (S0) to a higher level (S1,S 2, etc.) as shown
in Fig. 2. Molecules excited to upper singlet energy levels
(S2 etc.) rapidly (~10
−10 s) return to the lowest excited state
S1 without light emission, from which a number of
radiative (fluorescence) and non-radiative transitions can
occur to return the molecule to any of the rotational and/or
vibrational levels of the ground electronic state S0. The
transition from S1 to the triplet state T1 is referred to as
intersystem crossing and can be followed by relaxation to
S0 either radiatively (phosphorescence) or non-radiatively. In
some circumstances T1 can transfer the excitation energy to
other species, for example chelated lanthanide ions (Eu
3+,
Tb
3+,D y
3+,S m
3+), from which ion luminescence can occur
[2]. This ligand–ion energy transfer is known as the antenna
effect, and enables the observation of relatively intense
luminescence signals from lanthanide ions, which absorb
energy only poorly in the absence of ligand. Eu
3+,t h e
lanthanide ion that is most commonly used in bioanalytical
applications, can accept energy from the ligand triplet state
into any of several lower energy
5Dj levels, with emission
then occurring via transition from
5D0 to any of the ground-
state levels
7Fj to give signals at several characteristic
wavelengths (Fig. 2)[ 3]. The efficiency of this energy
transfer and the intensity of the subsequent emission depend
on both the ligand and the ion in question, and in particular
on the energy gap between the ligand triplet level and the ion
accepting level and the ability of the ligand to shield the ion
from quenching inner sphere water molecules, as discussed
later from the perspective of ligand design (in the section
“Chelator design and lanthanide labeling of biomolecules”).
The key feature of lanthanide luminescence that renders
it interesting bioanalytically is that lanthanide ions have
exceedingly long-lived luminescence (μs to ms range),
because the corresponding transitions are Laporte-
forbidden. In comparison, luminescence from conventional
fluorescent dyes and sample interferences occurs on a
nanosecond scale. This unique feature means that lantha-
nide luminescence can be selectively measured even in the
presence of other luminescent substances by time-gating the
signal—that is, by only starting the acquisition cycle after
the more rapid background fluorescence has decayed
(Fig. 3). The benefit of this in terms of assay development
is that the sensitivity of an assay depends strongly on the
signal-to-background ratio that can be achieved. A high
background signal for blank control samples containing no
analyte worsens the limits of detection and quantification
for real samples and limits the linear quantification range of
an assay. Background in luminescence measurements arises
from various sources, including the sample vessel or
membrane, but the most important source in biological
assays is generally the sample matrix. This is particularly
the case for homogeneous assays in which interfering
substances are not removed before measurement. A typical
biological sample, for example serum or a tissue sample,
Fig. 1 Two representative immunoassay formats—a heterogeneous
sandwich immunoassay (left) and a homogeneous immunoassay based
on LRET between two luminescent labels (indicated by purple arrow;
right). Antibodies labeled with tags (teardrop) are used for detection
of antigens (circles)
Fig. 2 Luminescence emission
processes of a general europium
chelate. An antenna ligand
absorbs the excitation energy
and transfers it to the T1 level
via intersystem crossing, from
which it is transferred to the
chelated Eu
3+ and emitted via
several transitions
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ple proteins and NAD
+/H [4, 5], and the detection limits of
various fluorophore–protein conjugates in serum have been
reported to be 50 to 1000-fold higher than in buffer [6].
However, the vast majority of these interferences have
standard short-lived fluorescence and can be filtered out by
time-gated detection. This also has the consequence of
broadening the linear range that can be achieved. Scattering
of the excitation light by the instrument optics, sample
vessel, and matrix is an additional problem with conven-
tional fluorophores, because of their generally small Stokes
shifts (<50 nm); this is circumvented by using lanthanide
chelates (>150 nm). A final problem with conventional
fluorophores is self-quenching because of substantial
overlap between their excitation and emission spectra,
meaning that multiply-labeled biomolecules fluoresce
much less than might be expected from the degree of
labeling. With their large Stokes shifts, narrow emission
bands, and no overlap between excitation and emission
spectra,lanthanidechelatesare not susceptible tothisproblem
and so are ideal candidates for highly sensitive protein-
detection assays.
In the field of lanthanide-based time-resolved lumines-
cence (TRL) immunoassays, the most common solid phases
are microtitre plates. This has the practical advantage in terms
of instrumentation that TRL capability can be incorporated
into luminescence plate readers that are also capable of
measuring other luminescence phenomena, for example
fluorescence polarization or chemiluminescence. This pro-
vides a convenient and cost-effective measurement solution
for the end user. A number ofdifferentplate readers withTRL
measurement modes exist today. They vary in respect of the
type of excitation sources, filters and/or monochromators,
time-gating, and focus setups used. Excitation sources can be
eitherflash lamps,lasersorUV-LEDs, althoughcombinations
of excitation sources (flash lamp plus UV-LED) do exist in
some instruments in order to combine sensitivity with high
flexibility(e.g. SpectraMax Paradigm,MolecularDevices). In
particular, the strong 337 nm emission of a nitrogen laser is
suitable for most europium chelates. Depending on the
excitation source, instruments are either filter-based or
monochromator-based. Whereas filter-based devices are
generally regarded as more sensitive, they are not as flexible
as monochromator-based devices (e.g. the Infinite m1000
system from Tecan). The time-delayed detection of the
fluorescence signal is normally achieved by oscillator-
controlled electronic devices. The strategy here is to ignore
photon counts which arrive at the detector before a specific
timepoint. A general challenge in TRL readers is the need for
photomultiplier tubes withexceptionallylow darkcount rates.
This is because the photon output of lanthanide-based TRL
dyes is generally low compared with that of conventional
fluorophores. With the recent development of various
lanthanide based immunoassays as described below, more
and more TRL-capable plate readers are becoming commer-
cially available and more users are equipped to perform the
assays described below.
Chelator design and lanthanide labeling of biomolecules
Introduction
The use of lanthanide ions in immunoassays requires their
incorporation into the immunocomplex. This is achieved
via the use of chelating agents, either by direct labeling of
antibodies or by indirect labeling of secondary detection
reagents. One secondary detection reagent is streptavidin,
which can then be used with readily available biotinylated
antibodies. A lanthanide chelator for use in immunoassays
therefore consists of at least two parts—a chelating group
for binding the lanthanide ion and some functionality for
attachment to biomolecules. When the lanthanide-labeled
biomolecule must be intrinsically luminescent, an additional
sensitizing antenna moiety is required (as described in the
section “Lanthanide luminescence”). The need to integrate
the optimum requirements of each of these three components
into a single molecule—that is, to create a stable complex
which combines efficient light absorption, energy transfer,
and emission, and which can be conveniently attached to
biomolecules without interfering with their activity—is a
major challenge in this field of research and the key points
will be introduced in the section “Ligand requirements”.
Numerous examples of specific lanthanide chelates from
several structural classes will then be introduced in the
sections “Non-luminescent chelates”, “PAC-based lumines-
cent chelates”, “β-Diketone-based luminescent chelates”,
and “Other luminescent chelates”). The focus here will be
Fig. 3 General principle of time-resolved luminescence measurements
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potential to be applied to immunoassays rather than those
designed for, e.g., electroluminescent materials applications,
which have been excellently reviewed elsewhere [7].
Ligand requirements
Chelating groups
To incorporate lanthanide ions into luminescent complexes,
chelating groups are required. Trivalent lanthanide cations
Ln
3+ are hard Lewis acids with a coordination number of
8–9[ 8], requiring hard donors, for example carboxylates,
β-diketonates and phosphonates, which contain nitrogen
and oxygen donor atoms. Although lanthanide ions can be
complexed by monodentate or bidentate ligands (e.g. 2-
thenoyltrifluoroacetone, salicylic acid) and such complexes
find application in some assays (described in the section
“Heterogeneous assays”), most practical systems rely on
the ability to carry the lanthanide ion as a “tag” on the
biomolecule through the various assay steps. This implies
that the complex has sufficient stability under the various
assay conditions, and generally necessitates the use of
multidentate chelators.
One major class of such chelators are the polyaminocar-
boxylates (PACs), for example the linear ethylenediaminete-
traacetic acid (EDTA) and diethylenetriaminepentaacetic acid
(DTPA) and their cyclic counterparts 1,4,7,10-tetraazacyclo-
dodecane-1,4,7,10-tetraacetic acid (DOTA) and 1,4,8,11-
tetraazacyclotetradecane-1,4,8-triacetic acid (DO3A)
(Fig. 4). These are the archetypal metal-sequestering agents
that are used in a range of industrial applications and are
readily available, inexpensive, and form soluble and highly
stable complexes with lanthanides under basic conditions.
The high stability of the lanthanide–PAC complexes stems
from the ability of the multiple amine and carboxylate
coordinating centers to wrap around the metal ion, and
increases in the order EDTA<DTPA<DOTA with the
denticity and from La to Lu across the lanthanide series
with the decreasing ionic radius, with typical logK values for
the lanthanide complexes being 10
15–10
20,1 0
19–10
23,a n d
10
23–10
26 for EDTA, DTPA, and DOTA complexes,
respectively [9]. An additional advantage for the higher-
denticityPACsisthatsaturationofthelanthanidecoordination
sphere by the ligand excludes water and thereby minimizes
aqueous quenching. These ligands also contain several
possible derivatization points for installation of antenna
moieties and reactive groups (see below).
A second group of lanthanide chelators that have found
application in immunoassays are β-diketonates derived from
thecorrespondingβ-diketonesunderbasicconditions(Fig.4).
Simple β-diketonates have two oxygen atoms available for
coordination and tend to form 3:1 complexes with lantha-
nides, with the remaining vacant sites in the lanthanide
coordination sphere being occupied by water molecules.
Many of these ligands include aromatic antenna groups (see
below) and their lanthanide complexes are intrinsically
luminescent. Although a large number of lanthanide β-
Fig. 4 Selected chelating,
antenna, and protein-reactive
groups for labeling of
biomolecules with lanthanides
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these are useful as lanthanide tags for biomolecules, because
each β-diketone is only bidentate and the complexes
therefore have limited stability. In an attempt to overcome
this limitation, several tetradentate ligands have been created
which combine two β-diketones in one molecule, and these
species are sufficiently stable for use in immunoassays
(discussed in the section “PAC-based luminescent chelates”).
It is also worth noting here that, despite their limited
stability, the bidentate ligands are a crucial part of the
most successful lanthanide-based immunoassay reported
to date—the DELFIA system—where they serve as
solution ligands after dissociation of lanthanide tags from a
non-fluorescent chelate-containing immunocomplex (dis-
cussed in the section “Heterogeneous assays”). In particular,
β-naphthoyltrifluoroacetone and 2-thenoyltrifluoroacetone
form intensely luminescent complexes with Eu
3+ and Tb
3+,
although a minor disadvantage of these ligands compared
with PACs is that it is usually necessary to use an auxiliary
ligand such as trioctylphosphine oxide (TOPO) in order to
saturate the remaining sites in the lanthanide coordination
sphere and exclude water [11, 12].
Several additional lanthanide chelates beyond these two
main classes have also been reported; these bind to
lanthanides via multiple carboxylates and one or more
aza-aromatic groups (e.g. pyridine, 2,2′-bipyridine, 1,10-
phenanthroline) which function both as chelator and
antenna. This has been termed the chromophoric chelate
strategy [13], and includes the tris-bipyridyl cryptands [14]
and BCPDA (ε≈15,200 mol
−1 Lc m
−1 (325 nm)) [15] (see
below). By comparison, the pendant chromophore strategy
involves the grafting of one or more chromophores on to
one of the aforementioned multidentate chelators, for
example DTPA or DO3A. Two examples of ligands
developed using this strategy are DTPA-cs124 (ε≈
8000 mol
−1 Lc m
−1 (337 nm)) [16] and [EuL]H [17].
Although both strategies can lead to effective chelators, the
chromophoric chelate approach is considered preferable
because it places the antenna function in close proximity to
the metal and thereby facilitates rapid energy transfer [18].
Chromophoric chelates do however typically require
augmenting agents, for example F
−, to exclude water from
the first coordination sphere and optimize the luminescence
[19]. Furthermore, for applications requiring the highest
chelate stability the pendant chromophore strategy using
multidentate PACs and an appropriate sensitizer is probably
optimum (as discussed in the section “PAC-based lumines-
cent chelates”). In general, an optimum chelator for all
kinds of different systems does not seem to exist. All of the
chelator structures introduced here have been successfully
used to construct luminescent chelates for use in sensitive
assays, as will be discussed later (in the section “Microtitre
plate-based assays”).
Antennas
After incorporation of a suitable lanthanide ion into a
chelating complex, antenna regions are required to effi-
ciently transfer excitation energy to the lanthanide ion.
Such antenna groups consist of an highly π-conjugated
aromatic or heteroaromatic system which efficiently
absorbs light and transfers it to the lanthanide ion,
increasing the molar extinction coefficient from ca 1–
10 mol
−1 Lc m
−1 for the uncomplexed trivalent cation to ca
10
4–10
5 mol
−1 Lc m
−1 for a typical lanthanide–antenna
complex [18, 20]. Typical antenna ligands include naph-
thalene, 1,10-phenanthroline, and 2,2′-bipyridine (Fig. 4).
A systematic study of the complexes of 41 ligands with
Eu
3+ and Tb
3+ revealed that the energy of the ligand triplet
excited state is crucial in determining the sensitization
efficiency of an antenna and should be at least 1,850 cm
−1
higher than the lowest excited state of the lanthanide ion
[21]. A smaller energy gap leads to a reduced quantum
yield because of back energy transfer and quenching of the
antenna triplet level, whereas a higher energy gap is
acceptable because the energy transferred from the antenna
transitions through the non-radiative excited states until it
reaches the emittive level [18]. This energy gap require-
ment means that the choice of antenna depends somewhat
on the lanthanide ion being used, and the optimum antenna
for one lanthanide ion is seldom the optimum choice for
another. In addition it is highly desirable that the excitation
maximum of the antenna is above ca 350 nm, which
enables the use of less expensive glass rather than quartz
optics and avoids the excitation of other chromophores (e.g.
Trp, NADH) in biological media. This is still a challenge in
the development of new lanthanide-based dyes.
Reactive groups for coupling to biomolecules
There are essentially only two generally applicable chemical
strategies for selective and efficient covalent attachment of
luminophoresorother small molecules to proteins—via either
Lys amino groups (using e.g. active esters, isothiocyanates) or
Cys thiols (using e.g. maleimides, iodoacetamide) (Fig. 4).
These activated derivatives are ideally relatively stable under
anhydrous conditions and can be conveniently coupled to
proteins at neutral to slightly basic pH. Unlike conventional
fluorophores, lanthanide chelates are seldom susceptible to
self-quenching, and so it is generally desirable to incorporate
as many lanthanide labels as possible into the final
immunocomplex as can be achieved without affecting the
immunological binding or physical properties (e.g. solubil-
ity). The maximum labeling degree that can be achieved
depends on the protein, chelate, and reaction conditions in
question, but 4–15 labels for a 150 kDa antibody using a
simple PAC derivative is typical [22].
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antibody involves the use of labeled streptavidin as a universal
detection system, because its binding affinity for biotin seems
to tolerate higher labeling degrees, in addition to enabling a
multivalency effect via multiply biotinylated antibodies [12,
23–26]. In a particularly extreme case, a macromolecular
conjugate consisting of streptavidin, three units of thyroglob-
ulin, and 480 lanthanide chelates has been reported [27, 28].
A novel recent alternative to labeling biomolecules
with luminescent chelates that has recently emerged is
the surface coating of a submicrometer luminescent bead
with the biomolecule. Polystyrene beads (107 nm) con-
taining >30,000 europium(III)–2-thenoyltrifluoroacetone
complexes per particle are commercially available and
have a carboxylic acid surface which can be used for
covalent attachment of streptavidin or antibodies [29, 30].
The hydrophobic interior of such beads minimizes
aqueous quenching and high luminescence intensities are
obtained.
Although some of the labeling strategies lead to higher
numbers of lanthanide dyes per protein than others, it is
clear that coupling of lanthanide dyes to proteins is now a
very well established technique and not a major challenge
in terms of lanthanide dye compatibility in the field of
immunoassays.
Non-luminescent chelates
The concept of using lanthani d ec h e l a t e sa sl a b e l si n
immunoassays was suggested thirty years ago by Wieder
[31] and then by Soini and Hemmilä [6], and finally
realized in 1983 with the advent of the DELFIA system
[32]. This relies on a non-luminescent lanthanide tag
which is liberated before measurement by addition of an
enhancement solution. As such, simple reactive EDTA or
DTPA-derived chelators which lack an antenna function
can be utilized, for example cyclic DTPA anhydride (c-
DTPAA), p-SCN-Bn-DTTA, and p-SCN-Bn-DTPA
(Fig. 5). A compromise is required here between the need
for chelate stability during storage and washing steps and
rapid release of the lanthani d eb e f o r em e a s u r e m e n t ;o n e
study revealed p-SCN-Bn-DTTA to be the optimum
choice of those tested [33]. In this case, labeling degrees
of 15–25 Eu
3+ chelates per IgG were achieved and
dissolution was achieved within 1 min of addition of the
enhancement solution. Although c-DTPAA is a readily
available and inexpensive alternative, it is poorly soluble
and the reaction is difficult to control and may result in
crosslinking of the biomolecule. A method for utilizing
DOTA derivatives in the DELFIA system has also recently
been reported; this uses a treatment step with 2.0 mol L
−1
HCl to release lanthanides from these more stable chelates
before measurement [34]. A major advantage of the
DELFIA system is the relative ease with which multi-
plexing can be achieved, because the same simple chelates
can be used with any of the luminescent lanthanide ions,
assuming enhancement solutions are available for all
lanthanides present (typically Eu
3+,T b
3+,D y
3+,S m
3+).
PAC-based luminescent chelates
A convenient means of preparing luminescent lanthanide
chelates is to attach an antenna moiety to one of the
carboxylates of DTPA, because the resulting product still has
sufficiently high denticity to form stable chelates. Reaction of
c-DTPAA (Fig. 5) with the commercially-available sensitizer
carbostyril 124 (ε=12,000 mol
−1 Lc m
−1(327 nm)) afforded
DTPA-cs124 (Fig. 6), which forms luminescent complexes
with both Eu
3+ and Tb
3+ [35]. The remaining anhydride of c-
DTPAA can also be reacted with diamines and further
converted to an isothiocyanate or maleimide derivative to
enable facile coupling to proteins or DNA [36, 37].
Likewise, the recent synthesis of the ligand [EuL]H
(Fig. 6) relied on attachment of a 1,10-phenanthroline-based
sensitizer to c-DTPAA and subsequent reaction of an
additional carboxylate with a maleimide derivative [17].
Coupling of the maleimide to proteins and incubation with
Eu
3+ enabled the detection of 100 amol lysozyme on PVDF
membranes and 1.5 fmol BSA in SDS-PAGE gels, and a
linear range spanning five orders of magnitude was
Fig. 5 Non-luminescent
lanthanide chelators for use in
DELFIA assays
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unusually wide range, making it compatible with a wide
range of excitation sources from 310–365 nm.
β-Diketone-based luminescent chelates
Although simple β-diketones do not form sufficiently
stable complexes to be used as labeling reagents, incorpo-
ration of two β-diketones into one molecule gives a
tetradentate ligand which can be successfully used in
immunoassays. The β-diketone units are held in place by
a rigid or flexible spacer and also contain an aromatic or
heteroaromatic antenna function; several such ligands have
been developed (Fig. 7). The first example was BCDOT,
which contains two biphenyl antennas for efficient light
absorption (ε=36,500 mol
−1 Lc m
−1(330 nm)) and two
sulfonyl chloride moieties for coupling to proteins [38]. For
the BSA–BCDOT47–Eu complex the detection limit was
83 fmol L
−1 in TOPO–SDS–NaHCO3 solution and the
method was shown to be linear over at least four orders of
magnitude. The same authors subsequently developed the
ligand BCOT, which was found to have similar properties
for the free complex (ε=32,000 mol
−1 Lc m
−1 (330 nm))
and the BSA–BCOT40–Eu conjugate (detection limit
95 fmol L
−1)[ 39]. In both cases the luminescence intensity
was enhanced by the synergistic TOPO ligand, partially
quenched by phosphate, and resistant to dissolved oxygen.
The thiophene-containing BCTOT has been used similarly
[40]. All three ligands suffer from the disadvantage that the
two sulfonyl chloride groups can potentially cause cross-
linking of the proteins being labeled, although this can be
avoided by prior blocking of one group by use of simple
amines [38].
A second series of ligands containing more rigid
terphenyl structures between the two β-diketones has also
been developed (Fig. 7). A detection limit of 6.5 fmol L
−1
was reported for BSA–BHHCT35–Eu [41]. Subsequent
work revealed that the luminescence intensity could be
increased eightfold by exchanging the C3F7 groups in
BHHCT for CF3 groups in BTBCT [42]. Potential draw-
backs of these ligands include their poor aqueous solubility
and the high reactivity of the sulfonyl chloride group,
which may lead to poor reagent stability during storage or
result in excessive labeling degrees and loss of bioactivity
of the labeled molecules. In an attempt to develop a more
mild reagent, the NHS ester derivative BHHST has also
been prepared and found to have improved solubility and
Fig. 6 Luminescent PAC-based lanthanide chelators
Fig. 7 β-diketonate-based lanthanide chelating agents. Abbreviations:
BTBCT, 4,4′-bis(1″,1″,1″-trifluoro-2″,4″-butanedion-4″-yl)-chloro-
sulfo-o-terphenyl; BPPCT, 4,4′-bis(1″,1″,1″,2″,2″-pentafluoro-3″,5″-
pentanedion-5″-yl)-chlorosulfo-o-terphenyl; BHHCT, 4,4′-bis
(1″,1″,1″,2″,2″,3″,3″-heptafluoro-4″,6″-hexanedion-6″-yl)-chloro-
sulfo-o-terphenyl; BHHST, 4,4′-bis(1″,1″,1″,2″,2″,3″,3″-heptafluoro-
4″,6″-hexanedion-6″-yl)-sulfonylaminopropyl ester-N-succinimide
ester-o-terphenyl; BCDOT, 1,10-bis(4″-chlorosulfo-1,1″-diphenyl-4′-
yl)-4,4,5,5,6,6,7,7,-octafluorodecane-1,3,8,10-tetraone; BCOT, 1,10-
bis(8′-chlorosulfodibenzothiophene-2′-yl)-4,4,5,5,6,6,7,7,-octafluoro-
decane-1,3,8,10-tetraone; BCTOT, 1,10-bis(5′-chlorosulfothiophene-
2′-yl)-4,4,5,5,6,6,7,7,-octafluorodecane-1,3,8,10-tetraone
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BHHCT [43]. Some of these β-diketone ligands have also
been successfully used to generate sensitive immunoassays,
which will be the focus of the section “Surface measure-
ment of directly luminescent chelates”.
Other luminescent chelates
BCPDA is a sulfonyl chloride-activated bathophenanthro-
line derivative (Fig. 8) and has been commercialized as part
of the CyberFluor FiaGen product line [15]. The BCPDA–
Eu complex has a moderate extinction coefficient at 325 nm
(ε≈15,200 mol
−1 Lc m
−1) and a long lifetime (0.44–
0.76 ms) depending on conditions, with a luminescence
that is again quenched by phosphate ions but insensitive to
dissolved oxygen. A BSA–BCPDA39–Eu conjugate has
been prepared, and crosslinking between the twin sulfonyl
chlorides was not observed. The detection limit for free
BCPDA–Eu is approximately 10 pmol L
−1 [15]b u t ,
because most assays have relied on multiply-labeled
streptavidin conjugates as a universal detection system,
the actual detection limit is somewhat lower [12, 23–26]. A
streptavidin–thyroglobulin3–BCPDA480 conjugate has also
been reported [27, 28]. Although such heavily labeled
conjugates provide access to lower detection limits, non-
specific binding of these large macromolecules to solid
supports can present problems [44]. Measurements in these
assays are typically performed in a dry well-plate using an
excess of added Eu
3+, meaning that contamination by
exogenous Eu
3+ is not an issue, which can be an advantage
compared with the DELFIA system.
The Cis-Bio cryptate (Fig. 8) is a macropolycyclic ligand
containing three bipyridine ligands with a dual chelator–
antenna function, forming a cavity which is able to
encapsulate Eu
3+ and Tb
3+ ions to form luminescent
complexes [14]. Although this cavity results in tight metal
chelation, the limitations of this system include the fact that
addition of relatively large amounts of fluoride ions is
necessary to exclude water molecules, and the excitation
wavelength (307 nm) is somewhat shorter than desired.
Nevertheless, europium complexes have found application
as donors in homogeneous assays, for example the time-
resolved amplification of cryptate emission (TRACE) and
homogeneous time-resolved fluorescence (HTRF) assays
from CisBio (described in the section “Homogeneous
assays”)[ 45–47].
Chelate design: overview
A wide variety of different chelator, antenna, and protein-
reactive structures are available for construction of lantha-
nide chelates for sensitive time-resolved luminescence
assays, with the optimum system depending on the precise
assay requirements. For DELFIA systems any of several
non-luminescent PACs provide sufficient stability to carry
the lanthanide tag through all requisite washing steps before
luminescence development. Simple DTPA derivatives are
generally preferred here, although luminescence develop-
ment methods have also been established that enable the
exploitation of the more stable DOTA derivatives. For
assays requiring intrinsically luminescent chelates, this can
be achieved either by simply grafting an appropriate
antenna on to a PAC skeleton in the pendant chromophore
strategy, or by using β-diketonate or heteroaromatic-
containing antennas in the chromophoric chelate strategy.
All of these routes have been shown to be capable of
leading to lanthanide chelates that have sufficient stability,
luminescence, and protein reactivity for the construction of
sensitive immunoassays. It is worth noting here that the
brightness (i.e. the product of quantum yield and extinction
coefficient) of lanthanide-based luminophores is generally
low compared with those of conventional fluorophores such
as fluorescein. However, this potential limitation is over-
come by the effective suppression of background signals
provided by the time-gated detection, giving a net effect of
increased dynamic range and more sensitive assays, as will
be the focus of the next section.
Microtitre plate-based assays
Heterogeneous assays
Luminescence enhancement-based assays
The most commercially successful lanthanide-based immu-
noassay developed to date is the dissociation-enhanced
lanthanidefluorescenceimmunoassay(DELFIA)fromWallac
Oy, which can be used in heterogeneous competitive or non-
competitiveformats.Inthissystemanon-fluorescentchelator, Fig. 8 Structures of BCDPA and the Cis-Bio bipyridine cryptate
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cent chelates”), is used to quantitatively carry the lanthanide
tag through the immunoassay and luminescence is only
developed before measurement upon addition of an enhance-
ment solution. This consists of an antenna-containing β-
diketone ligand (e.g. β-naphthoyltrifluoroacetone, NTA), a
synergistic agent to exclude water from the lanthanide
coordination sphere (e.g. trioctylphosphine oxide, TOPO),
and a non-ionic detergent (e.g. Triton X-100) in an acidic
phthalate buffer [48], which causes rapid dissociation of the
lanthanide from the immunocomplex and forms a strongly
luminescent micellar solution complex. All four of the
luminescent lanthanides (Dy, Eu, Sm, Tb) can be utilized
in the DELFIA assay, but differences in the emissive levels
of the different ions necessitates use of different ligands and
means that a single enhancement solution is not optimum for
all ions. The detection limit for the micellar Eu
3+–NTA
complex (ex. 340 nm, em. 613 nm, Ф=0.7) is of the order of
50 fmol L
−1 [48], and Eu
3+ is the lanthanide of choice for
single analyte assays. This leads to protein detection limits in
the low ng L
−1 range (Table 1). Sm
3+ also forms luminescent
complexes with NTA, albeit with 70-fold lower sensitivity
(LOD 3.5 pmol L
−1), and is the preferred second lanthanide
for dual analyte assays [49]. For detection of three or four
analytes, Eu
3+ and Sm
3+ luminescence can be measured in
an initial step via their NTA complexes, followed by
measurement of Tb
3+ and Dy
3+ after addition of the
dipicolinic acid ligand (4-(2′,4′,6′-trimethoxyphenyl)pyri-
dine-2,6-diyl)dicarboxylic acid [50]. Four analyte assays
can also be constructed using cofluorescence enhancement-
based systems, in which inter-chelate energy transfer occurs
from nearby non-luminescent lanthanide chelates, for exam-
ple Gd
3+ or Y
3+ [49]. Both the two-step and one-step
methods deliver detection limits in the 20 fmol L
−1–
20 pmol L
−1 range for the four lanthanides. Three of the
four luminescent lanthanides can also be efficiently sensi-
tized by pivaloyltrifluoroacetone (LOD 0.4–20 pmol L
−1)
but this is an inefficient ligand for Dy
3+ (LOD 1 nmol L
−1).
Besides its sensitivity and capacity for multiplexing, the
DELFIA system has several additional advantages, including
the commercial availability of all necessary protein labeling
reagents and streptavidin–lanthanide conjugates, microtitre
plates, assay buffers, and enhancement solutions. The
solution-based measurement also minimizes any potential
discrepancies arising from surface heterogeneity. One major
limitation of the DELFIA system is the loss of spatial
localization that results from the dissociation step, meaning
that it cannot be applied to surface-based measurements
(discussed in the section “Surface-based assays”). Contami-
nation by exogenous lanthanide is also a problem and can
affect assay reproducibility [51], although the relatively high
ca 1 nmol L
−1 Eu
3+ concentration in human serum [52]
should, in principle, be washed away during heterogeneous
assays and not affect reproducibility. A minor practical
disadvantage of the DELFIA system is the somewhat
extensive washing required compared with conventional
immunoassays. A typical lanthanide labeling degree is 15–
25 chelates per IgG [33], and there does not seem to be any
attempt in the literature to use, e.g., streptavidin–carrier
protein conjugates to increase the number of lanthanide ions
per immunocomplex. The same effect might also be
achievable using macromolecular dendritic or polymeric
chelators that could be bound to a detection antibody using
the biotin–streptavidin interaction. Such a strategy could
potentially dramatically increase the sensitivity of DELFIA
assays by maximizing the signal intensity.
Surface measurement of directly luminescent chelates
The use of intrinsically luminescent lanthanide-containing
detection reagents has several advantages compared with
dissociation-enhanced solution measurements, including a
reduction in the number of assay steps and washing cycles.
The first such system developed was the CyberFluor
FIAgen assay, which uses BCPDA-labeled (discussed in
the section “Other luminescent chelates”) tracers, for
example, streptavidin or streptavidin–thyroglobulin conju-
gates as widely applicable generic detection reagents [23,
24]. Luminescence is measured on the solid phase after
drying in an excess of Eu
3+, which is necessary because of
the limited chelate stability. An advantage of this is that the
measurement is insensitive to exogenous Eu
3+ contamina-
tion. Furthermore, because of the large Stokes shift and
corresponding insensitivity to self-quenching, these tracers
can be synthesized with surprisingly high BCPDA loadings
(15 BCPDA per streptavidin or 160 BCPDA per streptavi-
din–thyroglobulin conjugate) resulting in improved detec-
tion limits. In fact, the luminescence emitted per
luminophore seems to increase upon increased loading,
such that the TG-BCPDA160 emits luminescence equivalent
to 900 free BCPDA molecules [53]. In a non-competitive
heterogeneous α-fetoprotein assay, the detection limits
were improved fivefold compared with directly-labeled
IgG by using streptavidin-BCPDA15, and fivefold again
by using the streptavidin–TG–BCPDA160 conjugate
(Table 1). A macromolecular streptavidin–TG3.3–BCPDA480
aggregate has also been prepared and shown to afford 8–
26-fold reduced detection limits for seven different analytes
[27]. A more recent development has been the use of
streptavidin–polyvinylamine conjugates bearing 50–100
BCPDA moieties, resulting in detection limits of 1 ng L
−1
for PSA and a linear range spanning four orders of
magnitude [54, 55]. This tracer seems to be optimum at
present, although detection limits in the low ng L
−1 range
have been reported for several proteins using the other
macromolecular conjugates, and dynamic ranges for
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Analyte Reporter Detection limit Working range Ref.
DELFIA
Rabbit IgG IgG–diazophenyl–EDTA–Eu 25 ng L
−1 – [48]
IgG–SCN–Bn–EDTA–Eu
Hepatitis B surface antigen IgG–diazophenyl–EDTA–Eu 500 ng L
−1 >2 [32]
Staphylococcal Enterotoxin B Unspecified IgG–Eu9.4 conjugate 39 ng L
−1 >2 [51]
Yersinia pestis-specific F1 antigen Unspecified IgG–Eu6.8 conjugate 24 ng L
−1 >3 [51]
Venezuelan equine encephalitis virus Unspecified IgG–Eu4.8 conjugate 3.13x10
9 PFU L
−1 >1 [51]
Lipoprotein(a) IgG–(DTTA)21–Eu 2500000 ng L
−1 >2 [88]
PSA IgG–(N1–ITC–Eu)23 3.0 ng L
−1 >3 [57]
Clenbuterol IgG–DOTA–Eu 10000 ng L
−1 >2 [89]
Hydrocortisone IgG–DOTA–Tb 40000 ng L
−1 >1
Atrazine (comp.) IgG–W8044–Eu 100 ng L
−1 – [90]
FIAgen
Rubella IgG SA–BCPDA14–Eu 10000 IU L
−1 – [28]
Thyroxine-binding globulin SA–BCPDA–Eu 400 μgL
−1 >2 [26]
α-fetoprotein IgG–BCPDA–Eu 5000 ng L
−1 – [53]
α-fetoprotein SA–BCPDA14–Eu 1000 ng L
−1 – [53]
α-fetoprotein SA–TG–BCPDA160–Eu 200 ng L
−1 – [53]
Choriogonadotrophin SA–BCPDA–Eu 1 IU L
−1 >2 [24]
Human pancreatic isoamylase SA–TG–BCPDA–Eu 1100 ng L
−1 >2 [91]
Growth hormone SA–TG3.3–BCPDA480–Eu 3 ng L
−1 – [27]
Carcinoembryonic antigen SA–TG3.3–BCPDA480–Eu 11 ng L
−1 – [27]
PSA SA–B–PVA–BCPDA 1 ng L
−1 4[ 54, 55]
Cortisol (comp.) SA–BCPDA15–Eu 10000 ng L
−1 >1 [25]
Digoxin (comp.) SA–TG–BCPDA150–Eu 250 ng L
−1 >1 [92]
β-diketones
α-fetoprotein SA–BHHCT21–Eu 4.1 pg L
−1 – [41]
Thyroid-stimulating hormone SA–BSA1.8–BTBCT77–Eu 0.1 mIU L
−1 >3 [42]
T4 (comp.) T4–BSA–BTBCT23–Eu 5.8 nmol L
−1 – [42]
T4 (comp.) T4–BSA–B, SA–BCTOT–Eu 6.7 nmol L
−1 – [40]
Nanoparticle-based
PSA SA-coated Eu(β-NTA)3-doped polystyrene NPs 1.6 ng L
−1 4[ 56]
PSA IgG-coated Eu(β-NTA)3-doped polystyrene NPs 0.21 ng L
−1 4[ 57]
Adenovirus IgG-coated Eu(β-NTA)3-doped polystyrene NPs 5650000 virus
particles L
−1
4[ 58]
Hepatitis B surface antigen (HBsAg) IgG-coated Eu(β-NTA)3-doped polystyrene NPs 28 ng L
−1 4[ 59]
Listeria spp. IgG-coated Eu(β-NTA)3-doped polystyrene NPs 20000 CFU L
−1 4[ 60]
Anthrax PA SA-coated polystyrene NPs, biotinylated anti-SA, SA–Eu 10 ng L
−1 4[ 61]
Hepatitis B surface antigen (HBsAg) F(ab)2-coated Eu(β-NTA)3-doped polystyrene NPs 0.013 ng L
−1 4[ 62]
Anti-HIV-1 IgG Pyridine-based Tb chelate-labeled HIV-1 antigen n.d. –
Enzyme-amplified lanthanide luminescence
α-fetoprotein IgG–ALP 1.4 ng L
−1 >2 [67]
Salicylphosphate/salicylic acid/Tb–EDTA
α-fetoprotein Bt–pAb/SA–ALP 0.15 ng L
−1 >2 [68]
5-fluorosalicyl phosphate/5-fluorosalicylic acid/Tb–EDTA
α-fetoprotein IgG–ALP 3 ng L
−1 >2 [66]
Diflunisal phosphate/diflunisal/Tb–EDTA
Interleukin 6 SA–ALP 0.5 ng L
−1 (serum) – [69]
Diflunisal phosphate/diflunisal/Tb–EDTA
PSA SA–ALP 2 ng L
−1 – [70]
Diflunisal phosphate/diflunisal/Tb–E D T A 1 0n gL
−1 (serum)
comp. = competitive
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orders of magnitude (Table 1).
Several of the β-diketone ligands (discussed in the
section “β-Diketone-based luminescent chelates”)h a v e
also been used in immunoassays. Streptavidin-BHHCT21
has been developed as a generic detection reagent for
luminescence measurement on either the solid phase or in
solution after dissolution of the immunocomplex from the
well plate [41]. For α-fetoprotein solid and solution phase
detection limits of 46 pg L
−1 and 4.1 pg L
−1, respectively,
were obtained (Table 1), which are at least four orders of
magnitude lower than the aforementioned BCPDA-based
assay and also superior to previous α-fetoprotein assays. A
streptavidin-BSA1.8–BTBCT77 conjugate has also been
prepared and used for zeptomole detection of hTSH in a
sandwich assay and found to give results comparable with
those from a DELFIA-based system [42]. Two competitive
assays for serum T4 have also been developed using T4–
BSA–BTBCT23 or T4–BSA–biotin/streptavidin–BCTOT as
competing analytes to give low nmol L
−1 detection limits,
which is sufficient for clinical diagnosis [40, 42].
Intrinsically luminescent lanthanide chelate-labeled de-
tection reagents therefore provide an effective means of
increasing sensitivity and linear range in immunoassays for
a variety of different analytes. Performing luminescence
measurements on a well plate surface necessitates a
sufficient amount of tracer being present in the immuno-
complex, and a greater number of lanthanide tags can
typically be installed in biomolecules than conventional
fluorophores, because of the lack of self-quenching. The
number of lanthanide ions per immunocomplex can be
increased even further by using extensively labeled
proteins or other carrier macromolecules, although this
has yet to be exploited for other dyes besides BCPDA
and may be an attractive means of increasing sensitivity
in other assays.
Nanoparticle-based assays
An interesting alternative to labeling an antibody or generic
detection reagent with small-molecule lanthanide chelates
is, instead, to incorporate the luminescent chelates inside a
nanoparticle and coat the surface with the biomolecule.
This method has resulted in broad linear ranges over,
generally, four orders of magnitude and demonstrates the
usefulness of time-resolved luminescence measurement
especially in the field of protein detection. For example,
with a typical 107-nm polystyrene bead containing >30,000
Eu(III)–2-thenoyltrifluoroacetone complexes, a much
higher lanthanide-to-biomolecule ratio can be achieved
than by conventional methods. The potential of
streptavidin-coated luminescent nanoparticles was demon-
strated in a PSA assay, giving zeptomole (10
−21 mol)
sensitivity and a linear range spanning four orders of
magnitude (Table 1), a 100-fold increase over conventional
methods using Eu-labeled streptavidin [56]. A modest
increase in sensitivity was observed by using PSA-
specific IgG-coated NPs (Table 1)[ 57]. IgG-coated nano-
particles have also been used for detection of an adenovi-
rus, hepatitis B virus (HBsAg) and even bacteria (Table 1)
[58–60]. An interesting signal amplification method has
also been reported in a sandwich assay for anthrax toxin, in
which a biotinylated secondary antibody is first bound to a
streptavidin-coated luminescent nanoparticle before form-
ing a macromolecular complex using biotinylated anti-
streptavidin and streptavidin-Eu chelates [61].
Although these studies demonstrate the potential of
lanthanide-doped nanoparticles, an interesting future
development that has not been fully exploited is that of
multicolor assays utilizing several different lanthanides.
A dual analyte assay for hepatitis B surface antigen
(HBsAg) and human immunodeficiency virus 1 (HIV-1)
antibodies has been developed using F(ab)2-coated Eu
nanoparticles and a small molecule pyridine-based Tb
chelate-labeled antigen [62]. In a move toward an entirely
nanoparticle-based multiplexing assay, the synthesis of 45-
nm poly(styrene–acrylic acid) nanoparticles containing
each of the four luminescent lanthanides with appropriate
sensitizers (>1,000 chelates per nanoparticle) has been
r e p o r t e da n da p p l i e dt oa ni m m u n o a s s a yt og i v ed e t e c t i o n
limits for PSA of 1.6, 2.4, 10.1, and 114.2 ng L
−1 for the
Eu
3+,T b
3+,S m
3+ and Dy
3+-doped nanoparticles, respec-
tively [63]. One reason for the limited application of
polystyrene nanoparticles may be the less-than-optimum
physical properties of the polymer itself, which include
larger particle size, swelling, and leakage of the encapsu-
lated molecules through surface defects [64]. A dual-
lanthanide immunoassay for human and mouse IgG using
40 nm Eu-doped and Sm-doped silica nanoparticles has
recently appeared but these multiplexing techniques have
yet to be fully exploited [65]. These silica nanoparticles
have several advantages over latex-based ones, including
improved aqueous solubility and coupling chemistry,
because of the silanol surface [64].
Enzyme-amplified lanthanide luminescence (EALL)
EALL assays utilize an enzyme as label, which converts a
substrate into a product which is sufficiently different in
terms of its chelating or spectroscopic properties to enable
distinction between the two. The key advantage of this
technique compared with the hitherto discussed assay
formats is the enzymatic amplification step, although
substrate conversion itself necessitates an additional assay
step. Still, the potential for highly sensitive assays based on
EALL is certainly one of the most promising in the field.
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jugates to convert salicylic acid phosphates into the
corresponding salicylic acid derivative, the latter of which
forms a luminescent complex with Tb
3+ and EDTA. The
choice of substrate (Fig. 9, X substituent) depends on the
assay requirements, with more soluble substrates being
preferred for microtitre plate assays and more hydrophobic
substrates being preferred for surface-based assays where
signal localization is desired (discussed in the section
“Surface-based assays”). The X substituent also affects the
final luminescence properties of the chelate, and a
comparison of 14 different ligands revealed that diflunisal
(X=5-(2′,4′-difluorophenyl)) gave amongst the most in-
tense signals [66]. The limit of detection for ALP has been
reported as 0.2 amol [44], and the use of diflunisal and
related fluorinated substrates has led to detection limits in
the low ng L
−1 range for analytes such as α-fetoprotein,
interleukin 6, and PSA, even in serum (Table 1)[ 66–70].
These detection limits are at least equal to those using the
luminophore-labeled tracers discussed earlier and confirm
the value of EALL systems, especially when using widely
available antibody–ALP conjugates.
Besides the ALP-based assays, xanthine oxidase–salicy-
laldehyde and β-galactosidase–salicyl-β-D-galactoside sys-
tems can also be used to generate salicylic acid–Tb(III)–
EDTA complexes in solution [44]. These systems have
seldom been used, however, perhaps because of their
reduced sensitivity and the widespread availability of
antibody–ALP conjugates. Hemin-mediated dimerization
of p-hydroxybenzoic acid in the presence of H2O2 also
generates a species capable of sensitizing Tb(III)–EDTA,
although this has not yet been applied to an immunoassay
format [71]. EALL systems have yet to be extensively
developed for lanthanides other than Tb
3+, although
glucose oxidase-mediated hydrolysis of 1,10-phenanthro-
line-2,9-dicarboxylic acid dihydrazide to the corresponding
diacid has been shown to sensitize Eu
3+ [44]. One future
objective in this area is the continued development of
EALL systems which operate at neutral pH rather than the
strongly alkaline systems above which require addition of
EDTA to avoid precipitation of the lanthanide hydroxide,
because the EDTA itself sensitizes lanthanides to a small
extent and contributes to the background signal.
Homogeneous assays
Homogeneous immunoassays are potentially the most
convenient assay format, in principle requiring only
addition of the sample to the premixed reagents. Time-
resolved luminescence can be extremely beneficial for such
assays, because the inherently high background signals can
be minimized. However, sensitive assays are much more
difficult to achieve than with heterogeneous systems.
Homogeneous assays are generally based on some form
of LRET system, in which the presence of antigen either
displaces a donor or acceptor-labeled antigen analogue
Fig. 9 Enzyme-amplified
lanthanide luminescence. Top:
enzyme-mediated conversion of
a substrate into a product that
forms luminescent chelates with
lanthanides. Bottom: conversion
of salicylic acid phosphate
derivatives by ALP affords the
corresponding salicylic acid
which forms luminescent
chelates with Tb-EDTA
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to decrease in response to antigen concentration), or bridges
two labeled antibodies (causing LRET to occur in response
to antigen concentration; Fig. 1).
The most common system is the time-resolved amplifi-
cation by cryptate emission (TRACE; also known as
homogeneous time-resolved fluorescence, HTRF) system
developed by Cisbio International, which relies on a
europium cryptate label (Fig. 8) as donor and a crosslinked
allophycocyanin (XL665) as acceptor [45]. One surprising
benefit of this system is that the efficient LRET between
these two species actually results in a signal increase
compared with radiative deactivation of the isolated Eu
cryptate [46]. This system was first developed for an assay
for prolactin in which two IgGs were separately labeled
with the cryptate and XL665 [45]. In the presence of
analyte, 337 nm excitation of the cryptate is followed by
energy transfer to the XL665 which ultimately emits at
665 nm with a lifetime of 0.25 ms and can be measured and
compared with the reference 620 nm cryptate emission for
unbound IgG, resulting in a detection limit of 0.3 μgL
−1
prolactin (Table 2). A detection limit of <600 ng L
−1 for
interleukin-13 has also been obtained [47].
Small-molecule acceptors can also be used in LRET-
based systems. In a competitive assay for urinary albumin,
albumin-Cy5 was used as a tracer to accept energy from the
pyridine-based luminescent donor ITC–TEKES–Eu, giving
a rather high detection limit in the mg L
−1 range [72]. The
working range of this assay was nonetheless sufficient for
diagnosis of microalbuminuria.
Antibody Fab fragment-coated Eu
3+ chelate-doped
92 nm nanoparticles have been used in conjunction with
an estradiol–AlexaFluor 680 acceptor to detect pmol L
−1
levels of estradiol in a competitive assay [73]. Sensitivity in
this assay was increased 20-fold compared with assays
using soluble chelates [74]. Nanoparticle-based donors and
acceptors have also been combined in a PSA assay in
which anti-PSA antibodies on the two surfaces bring
together the donor and acceptor nanoparticles and lead to
a detection limit of 0.1 μgL
−1 [75].
The key benefit of using lanthanide complexes in
homogeneous assays arises from the fact that such assays
are ideally performed by direct addition of the biological
sample to the premixed assay reagents. In comparison with
heterogeneous assays in which background interferences
can be removed by multiple washing steps, these species are
stillpresentduringmeasurement ina homogeneousassay,and
the use of lanthanide chelates and time-gated acquisition
enables the background signal to be efficiently removed.
Surface-based assays
Despite the proven benefits of using lanthanide chelates
in microtitre plate-based assays, the extension of time-
resolved luminescence techniques to surface-based assays
has been less widespread. The ability to use lanthanide
chelates on surfaces used in key proteomics techniques,
for example membranes, gels, and tissue slices, would be
a major breakthrough, because these materials typically
have high autofluorescence backgrounds which could be
removed by using time-resolved techniques. However, a
lack of suitable instrumentation has hindered the devel-
opment of these techniques. This is especially true for
the time-resolved luminescence measurement of poly-
acrylamide gels, nitrocellulose, or PVDF membranes to
enable application of gel-based protein analysis systems,
for example immunoblot and SDS-PAGE. To the best of
our knowledge, only one instrument for time-resolved
fluorescence measurement of gels and membranes is
currently commercially available (SpectraMax Paradigm,
Molecular Devices). This prototype shows the high
potential of TRL measurements in gel-based analysis
systems [17]. Interestingly, a linear range of five orders of
magnitude was reported for this instrument, demonstrating
the high potential of time-resolved luminescence for
immunoblot applications.
The advantages of time-resolved luminescence detection
for microscopy studies, especially for highly autofluores-
cent tissue materials, are obvious. Surface-based assays
require intrinsically luminescent lanthanide chelates, be-
cause spatial resolution would be lost in a dissociation-
enhanced format. Although several europium-based stains
for visualization of tissue slices and membranes have been
Table 2 Detection limits and
working ranges for selected
homogeneous immunoassays
utilizing lanthanide-based
time-resolved luminescence
Analyte Reporters Detection limit Working range Ref.
Prolactin Donor: IgG–TBP–Eu 300 ng L
−1 – [45]
Acceptor: IgG–APC
Interleukin-13 Donor: IgG–Eu cryptate <600 ng L
−1 – [47]
Acceptor: IgG–biotin–SA–XL665
Albumin (comp.) Donor: IgG–TEKES–ITC2.7–Eu 5.5 mg L
−1 >1 [72]
Acceptor: albumin–Cy51.6
Estradiol (comp.) Donor: Fab-coated–Eu–chelate NP 70 pmol L
−1 – [73]
Acceptor: estradiol–Alexa 680
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labeled immunoreagents for dedicated specific surface-
based detection did not appear until 1988 [5]. In this case,
anti-rabbit IgG was labeled with a europium–W1014
chelate (structure unspecified) and used for immunohisto-
chemical staining using a conventional fluorescence micro-
scope. The use of dehydrated histological sections was
necessary because of aqueous quenching, and both intensity
and stability under steady-state excitation were inferior to
those of fluorescein-labeled IgG.
Full exploitation of the potential of lanthanide-labeled
biomolecules required the development of a luminescence
microscope capable of time-gated detection; this was first
applied to lanthanide-labeled biomolecules in 1990 [78].
These early experiments demonstrated that 100–300 nm
milled Eu
III-doped yttrium oxysulfide polycarboxylic acid-
stabilized nanoparticle phosphors coated with IgG or avidin
could successfully bind corresponding targets on latex
beads and cell surfaces. A similar prototype instrument
was developed and used for immunohistochemical analysis
of various specimens after staining with antisera and
streptavidin coupled to a pyridine-based europium chelate,
enabling efficient removal of background luminescence and
equal sensitivity to fluorescein-labeled and enzyme-labeled
antibodies [79]. Labeling of antibodies with the stable Eu–
W8044 chelate (structure unspecified) has also been found
to reduce the autofluorescence of glutaraldehyde-fixed
colon cancer cells and enable signal-to-background ratios
of 2400:1 to be obtained [80]. Likewise, Eu–terpyridine-
labeled antibodies have been shown to improve signal-to-
background ratios in islet cells by a factor of 12 compared
with conventional fluorescein-labeled antibodies [81].
Similarly, a Eu–terpyridine chelate has been attached to
anti-PSA antibodies and bound to prostate cells [82].
Several β-diketonate dyes have also been used for
microscopy studies. Antibodies labeled with BPPCT
(Fig. 7) have been used for detection of cysts of the
water-borne pathogen Giardia lamblia on filter membranes,
resulting in a 30-fold increase in contrast relative to
conventional immunoreagents [83]. Giardia and Crypto-
sporidium have also been detected by use of BHHST-
labeled antibodies, which resulted in tenfold enhancement
of signal-to-noise ratio [43, 84]. It has also been shown
recently that the luminescence of surface-based BHHCT
complexes is enhanced in the presence of silver nano-
structures, leading to twofold increased brightness during
detection of G. lamblia cells [85]. These techniques enable
sensitive detection of pathogens in environmental water
samples containing multiple autofluorescent species, for
example algae, mineral particles, and organic debris.
For generic detection reagents, streptavidin–thyroglobu-
lin–BCPDA (discussed in the section “Surface measurement
of directly luminescent chelates”) has been used for analysis
of tissue-bound biotinylated anti-myosin antibodies, and its
photostability has been reported to be superior to that of
previous chelates [86]. Streptavidin-coated Eu-containing
nanoparticles have also been used, enabling detection of
single nanoparticles using a TRL microscope [82]. In model
studies using biotinylated PSA, a linear range of two orders
of magnitude was reported, although the authors note that
biological variation is expected to constitute the major source
of error when attempting to quantify antigens in tissue
sections. An unspecified streptavidin–Eu chelate has also
been used for detection of biotin-tyramide after enzymatic
deposition by an antibody–peroxidase conjugate, enabling
signal amplification [87].
Considering all results described for surface-based assays,
it is clear that this area is an ideal field of application for time
resolved luminescence. However, few instruments are cur-
rently able to fully exploit this possibility.
Conclusions
The objective of this review has been to explain the benefits
of lanthanide-based time-resolved luminescence measure-
ments in immunoassays. Using time-gated acquisition the
background signal can be efficiently suppressed, enabling
more sensitive detection of proteins using lanthanide
chelate tags than is possible with chromophore-based or
conventional fluorophore-based labels. This ultimately
leads to lower detection limits and wider linear ranges for
the analyte in question. This is especially valuable for
protein detection where these criteria are of particular
importance and where high autofluorescence is normally
observed when time-gated detection is not used.
Although it is difficult to reliably compare sensitivities
reported for different lanthanide chelates obtained for
different analytes and assay configurations in different
laboratories, the heterogeneous DELFIA, FIAgen, nano-
particle, and EALL-based assays are all capable of
delivering sensitivity in the lower ng L
−1 range. For the
DELFIA system this is derived from an intensely lumines-
cent solution complex, whereas the other assays rely either
on the extensive incorporation of lanthanides into a multi-
protein complex or nanoparticle, or on enzymatic amplifi-
cation to increase the number of detectable labels per
immunocomplex. It would be interesting, therefore, to
investigate whether the sensitivity of the DELFIA system
could be increased even further by use of macromolecular
chelates that incorporate hundreds of lanthanide ions rather
than the 15–25 ions used with single antibodies. The
sensitivity of the EALL assays could also, perhaps, be
improved via more extensive testing of enzyme–substrate
pairs than the predominantly ALP–salicylic acid-based
systems that have been used to date. For the homogeneous
Lanthanide-based time-resolved luminescence immunoassays 2861assays that have been developed the sensitivity is typically
in the high ng L
−1 range, so these are more suitable for
applications where speed is more important than sensitivity.
Akeyadvantageoflanthanidetime-resolvedluminescence-
based assays is the increased linear range because of
suppression of the background signal, and many of the
heterogeneous assays discussed above are able, in principle,
to provide linear ranges spanning five orders of magnitude.
However, for the actual assays discussed here, linear ranges of
2–3 orders of magnitude are typical for the DELFIA, FIAgen,
β-diketonate, and EALL-based assays, with nanoparticle-
based assays consistently delivering linear ranges spanning at
least four orders of magnitude. With the difference between
high abundance and low abundance proteins spanning an
estimated twelve orders of magnitude [1], it is clear that
further improvements in instrumentation and assay develop-
ment are desirable here. In conclusion, more emphasis should
be given to the use of time-resolved luminescence as an ideal
tool to meet the unique challenges of the field of protein
detection, for example broad linear ranges, high sensitivity,
and excellent signal-to-background ratios.
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